Research graph
References from Sebetralstat for breakthrough attacks in patients with hereditary angioedema receiving long-term prophylaxis in KONFIDENT-S. Local targets link to admitted publications; unresolved targets remain external evidence.
US HAEA Medical Advisory Board 2020 guidelines for the management of hereditary angioedema
10.1016/j.jaip.2020.08.046 · 2021 · External reference
The international WAO/EAACI guideline for the management of hereditary angioedema—the 2021 revision and update
10.1111/all.15214 · 2022 · External reference
Fatal laryngeal attacks and mortality in hereditary angioedema due to C1-INH deficiency
10.1016/j.jaci.2012.05.055 · 2012 · External reference
Symptoms, course, and complications of abdominal attacks in hereditary angioedema due to C1 inhibitor deficiency
10.1111/j.1572-0241.2006.00492.x · 2006 · External reference
Hereditary angioedema attacks resolve faster and are shorter after early icatibant treatment
10.1371/annotation/ab8fe636-8b5b-420e-9cbf-1bef0a19b63f · 2013 · External reference
Efficacy of on-demand treatment in reducing morbidity in patients with hereditary angioedema due to C1 inhibitor deficiency
10.1111/all.12731 · 2015 · External reference
Response to ecallantide treatment of acute attacks of hereditary angioedema based on time to intervention: results from the EDEMA clinical trials
10.2500/aap.2011.32.3440 · 2011 · External reference
Effect of time to treatment on response to C1 esterase inhibitor concentrate for hereditary angioedema attacks
10.1016/j.anai.2013.06.021 · 2013 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2020 · External reference
Unresolved reference
2024 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2026 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2025 · External reference
Unresolved reference
2022 · External reference
Unresolved reference
2021 · External reference
Unresolved reference
2024 · External reference
Advent of oral medications for the treatment of hereditary angioedema
10.1002/clt2.12391 · 2024 · External reference
Hereditary angioedema attacks in patients receiving long-term prophylaxis: a systematic review
10.1007/s12016-024-09006-1 · 2024 · External reference
Pharmacokinetics, pharmacodynamics, and exposure-response of lanadelumab for hereditary angioedema
10.1111/cts.12806 · 2020 · External reference
Phase II study results of a replacement therapy for hereditary angioedema with subcutaneous C1-inhibitor concentrate
10.1111/all.12658 · 2015 · External reference
A randomized trial of human C1 inhibitor prophylaxis in children with hereditary angioedema
10.1111/pai.13060 · 2019 · External reference
Long-term outcomes with subcutaneous C1-inhibitor replacement therapy for prevention of hereditary angioedema attacks
10.1016/j.jaip.2019.01.054 · 2019 · External reference
Effect of lanadelumab compared with placebo on prevention of hereditary angioedema attacks: a randomized clinical trial
10.1001/jama.2018.16773 · 2018 · External reference
Oral once-daily berotralstat for the prevention of hereditary angioedema attacks: a randomized, double-blind, placebo-controlled phase 3 trial
10.1016/j.jaci.2020.10.015 · 2021 · External reference
Oral berotralstat for the prophylaxis of hereditary angioedema attacks in patients in Japan: a phase 3 randomized trial
10.1111/all.14670 · 2021 · External reference
Safety and efficacy of prophylactic nanofiltered C1-inhibitor in hereditary angioedema
10.1016/j.amjmed.2012.02.020 · 2012 · External reference
Oral sebetralstat for on-demand treatment of hereditary angioedema attacks
10.1056/nejmoa2314192 · 2024 · External reference
Long-term safety and effectiveness of sebetralstat: interim analysis of KONFIDENT-S open-label extension
10.1016/j.jaip.2025.08.020 · 2025 · External reference
Mitigating disparity in health-care resources between countries for management of hereditary angioedema
10.1007/s12016-021-08854-5 · 2021 · External reference
Hereditary angioedema: the economics of treatment of an orphan disease
10.3389/fmed.2018.00022 · 2018 · External reference
On-demand treatment of hereditary angioedema attacks: patient-reported utilization, barriers, and outcomes
10.1016/j.anai.2024.12.012 · 2024 · External reference
The complexities of decision-making associated with on-demand treatment of hereditary angioedema (HAE) attacks
10.1186/s13223-024-00903-w · 2024 · External reference
An international Delphi study on barriers to on-demand treatment of hereditary angioedema attacks
10.1002/clt2.70159 · 2026 · External reference
The Angioedema Quality of Life Questionnaire (AE-QoL)—assessment of sensitivity to change and minimal clinically important difference
10.1111/all.12900 · 2016 · External reference
